6-methoxy-9-[(1r,4r)-4-methylcyclohexyl]-N-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)-9H-pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidin-2-amine | 1401034-00-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 6-methoxy-9-[(1r,4r)-4-methylcyclohexyl]-N-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)-9H-pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidin-2-amine
• CAS: 1401034-00-1
• 化学式: C₂₅H₂₉N₇O
• 分子量: 443.552
• InChiKey: BSWDAWSAVMWHIA-JCNLHEQBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.52
• 重原子数：
  33.0
• 可旋转键数：
  4.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  89.78
• 氢给体数：
  2.0
• 氢受体数：
  8.0

文献信息

• FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3
  申请人：Chen Xiaoqi

  公开号：US20120244110A1

  公开（公告）日：2012-09-27

  Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R 1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.

  Formula I的化合物是CDK 4、CDK6和FLT3的有效抑制剂。这些化合物在治疗癌症和其他各种疾病条件方面非常有用。Formula I的化合物具有以下结构：其中R1是Formula IA、Formula IB、Formula IC或Formula ID的一个基团，其他变量的定义在此处提供。
• [EN] FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3<br/>[FR] DOUBLES INHIBITEURS TRICYCLIQUES FUSIONNÉS DE CDK 4/6 ET DE FLT3
  申请人：AMGEN INC

  公开号：WO2012129344A1

  公开（公告）日：2012-09-27

  Compounds of Formula (I) are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula (I) have the following structure: where R1 is a group of Formula (IA), Formula (IB), Formula (IC), or Formula (ID) and the definitions of the other variables are provided herein.

  式(I)的化合物是CDK4、CDK6和FLT3的有用抑制剂。这样的化合物在治疗癌症和各种其他疾病状况方面是有用的。式(I)的化合物具有以下结构：其中R1是Formula(IA)、Formula(IB)、Formula(IC)或Formula(ID)的一组，其他变量的定义在此处提供。
• Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor
  申请人：Acerta Pharma B.V.

  公开号：US20170224819A1

  公开（公告）日：2017-08-10

  Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms (PI3K-γ,δ, PI3K-γ, and PI3K-δ, a Janus kinase-2 (JAK-2) inhibitor, a cyclin-dependent kinase-4/6 (CDK4/6) inhibitor, and/or a Bruton's tyrosine kinase (BTK) inhibitor are described. In certain embodiments, the invention includes therapeutic combinations of a cyclin-dependent kinase-4/6 (CDK4/6) inhibitor and a BTK inhibitor, a PI3K-δ inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a JAK-2, PI3K-δ, and BTK inhibitor.
• US8623885B2
  申请人：——

  公开号：US8623885B2

  公开（公告）日：2014-01-07
• US9359355B2
  申请人：——

  公开号：US9359355B2

  公开（公告）日：2016-06-07